A new combination treatment for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests a new therapy that combines heat treatment, a vaccine targeting a specific gene mutation, chemotherapy, and an immunotherapy drug to see if it can help people with advanced pancreatic cancer that has spread to the liver or lungs. It is for people whose cancer no longer responds to standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced pancreatic cancer or cancer that has come back after surgery.
- Your tumor has a specific gene change called KRAS G12V (a blood or tissue test can confirm this).
- Your cancer has stopped responding to or you cannot tolerate standard chemotherapy (called gemcitabine-based or similar).
- Your cancer has spread to your liver or lungs.
- You are well enough to get around (performance status 0 or 1) and have a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
This trial tests a new approach that combines a special type of radiation therapy (called PRaG) with an immunotherapy drug to treat advanced pancreatic cancer that hasn't spread. The goal is to see if this combination can shrink or control the tumor and help you live longer.
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
This study tests a new treatment combining tumor destruction with heat/cold (ablation) and an immunotherapy drug (PD-1) for people whose pancreatic cancer has spread to the liver. The goal is to help the immune system fight the cancer better.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
This trial tests a cancer vaccine (ELI-002 7P) for people with pancreatic cancer that hasn't spread to other parts of the body. It may be given alone or with another drug (tislelizumab) that helps the immune system fight cancer. The goal is to see if these treatments can help keep the cancer from coming back after surgery or chemotherapy.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.